Member Info for arsenal58

Pap
Stop being a regulator
They employ people they don’t need volunteers
Tin hat

Wondering the same
Cannot understand why GSK dont up the anti and buy VEC
Although the board don’t seem to want to make the company flourish IMO

https://uk.advfn.com/cmn/fbb/thread.php3?id=11462155

Big time customers
Cheap compared to its peers
Institutions buying like no tomorrow

why Guy Walkley got the push !!!
For not excepting the much larger bid pre pandemic
This is a goer now at a much lower offer !!

Gallahers cross wins the 16.25 at Musselburgh
The industry will suffer a ten million plus loss
Ooohps

Its in the Daily Mail if you want to read it

Next stop four squids

Around £13.22

Closed at 35.42
5.77% down

Target i think
Blackrock topping up again??

DRUG
Dont be so dramatic it will bounce hard after this
103 p in divis too come before split
Divi cut too 70p maybe split will allow for someone to grab this outfit
Especially if the drug line is good
Give him an oscar lol

Quarterly dividends



The Board has declared a fourth interim dividend for 2020 of 23 pence per share (Q4 2019: 23 pence per share).



GSK recognises the importance of dividends to shareholders and aims to distribute regular dividend payments that will be determined primarily with reference to the free cash flow generated by the business after funding the investment necessary to support the Group's future growth.



The Board currently intends to maintain the dividend for 2021 at the current level of 80p per share, subject to any material change in the external environment or performance expectations.



At our Biopharma investor update in June we plan to set out in detail the growth prospects and financial outlook for the new Biopharma company over the medium term, including a detailed review of the pipeline we have been building over recent years. Alongside these we will provide details of a new distribution policy which reflects the optimised capital structure and investment priorities focused on delivering sustainable long-term shareholder value. We anticipate that this new policy will deliver competitive and attractive returns informed by appropriate earnings pay-out ratios through the investment cycle well covered by Free Cash Flow and, importantly, expected growth potential. We expect that aggregate distributions for GSK will be lower than at present. This new policy will be implemented for dividends paid in respect of 2022.



Payment of dividends

The equivalent interim dividend receivable by ADR holders will be calculated based on the exchange rate on 6 April 2021. An annual fee of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by the Depositary.



The ex-dividend date will be 18 February 2021, with a record date of 19 February 2021 and a payment date of 8 April 2021.

Distribution policy for new GSK to be implemented in 2022 to support growth and investment. Aggregate distributions expected to be lower than at presentNot good

business!!!!!
I think not !!!!
Absolute schiesse

Sold today BJ
Had a lovely gain sold on the spike and cleared up now
Major changes coming again in regulation
Be careful all

An earthquake

Not sells

Huge shake up in gambling laws

Its get out time tomorrow one would surmise